

## PRELIMINARY AMENDMENT

Prior to substantive examination, please amend the application as follows:

### IN THE CLAIMS

Please cancel claims 1-9, 12-19 and 22-28.

Kindly amend pending claims 10 and 20 as follows:

10. (Amended) An isolated polypeptide[, wherein the polypeptide is selected from the group consisting of:

- a<sup>1</sup>
- (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and
  - (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO:1 – 35] encoded by the polynucleotide of SEQ ID NO: 6.

20. (Amended) An isolated polypeptide [comprising an amino acid sequence selected from the group consisting of any one of the polypeptides from the Sequence Listing, the mature protein portion thereof, or the active domain thereof] encoded by the polynucleotide comprising a nucleic acid sequence which is 99% identical to the nucleic acid sequence of SEQ ID NO: 6.

a<sup>2</sup>

### REMARKS

Upon entry of the foregoing amendments, claims 10, 11, 20 and 21 are under consideration.

Support for the amendment to claim 10 appears at least in the originally filed claim 10. Support for the amendment to claim 12 appears at least at page 28, line 26 of the specification. Applicants respectfully submit that the pending claims are in a condition for allowance. The undersigned can be reached at 408-746-4536 if the Examiner wishes to discuss the response.

An early action on the merits is respectfully requested.